Clinical Trials Browser

Phase 2/3 × Lisaftoclax × 90 days × Clear all

NCT07597941 2026-06-04

Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute